Targeting p27Kip1 protein: Its relevance in the therapy of human cancer

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 6, 2011, Pages 677-693

  Borriello, Adriana ^a   Bencivenga, Debora ^a   Criscuolo, Maria ^a   Caldarelli, Ilaria ^a   Cucciolla, Valeria ^a   Tramontano, Annunziata ^a   Borgia, Alessia ^a   Spina, Annamaria ^a   Oliva, Adriana ^a   Naviglio, Silvio ^a   Della Ragione, Fulvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

cancer therapy; cyclin dependent kinases; p 27Kip1 metabolism; p27Kip1

Indexed keywords

ANASTROZOLE; BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMATINIB; PROTEIN KINASE P60; RETINOIC ACID; S PHASE KINASE ASSOCIATED PROTEIN 2; SALINOSPORAMIDE A; TAMOXIFEN; VORINOSTAT; ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, HUMAN;

BREAST CANCER; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG CANCER; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 79955859448     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.561318     Document Type: Review

References (131)

1. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;15:59-66
2. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994;78:67-74 (Pubitemid 24228301)
3. Slingerland J, Hengst L, Pan C, et al. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor-beta-arrested epithelial cells. Mol Cell Biol 1994;14:3683-94 (Pubitemid 24160776)
4. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25 (Pubitemid 23346378)
5. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16 (Pubitemid 23346377)
6. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49
7. Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12 (Pubitemid 29297917)
8. Lacy ER, Filippov I, Lewi WS, et al. p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat Struct Mol Biol 2004;11:358-64 (Pubitemid 38436801)
9. Lacy ER, Wang Y, Post J, et al. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division. J Mol Biol 2005;349:764-73 (Pubitemid 40725953)
10. Sivakolundu SG, Bashford D, Kriwacki RW. Disordered p27Kip1 exhibits intrinsic structure resembling the Cdk2/Cyclin A-bound conformation. J Mol Biol 2005;353:1118-28 (Pubitemid 41503276)
11. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 1999;293:321-31 (Pubitemid 29516173)
12. Flaugh SL, Lumb KJ. Effects of macromolecular crowding on the intrinsically disordered proteins c-Fos and p27Kip1. Biomacromolecules 2001;2:538-40 (Pubitemid 32707535)
13. Borriello A, Cucciolla V, Oliva A, et al. p27Kip1 metabolism: a fascinating labyrinth. Cell Cycle 2007;9:1053-61
14. Besson A, Gurian-West M, Schmidt A, et al. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004;15:862-76 (Pubitemid 38529656)
15. Baldassarre G, Belletti B, Nicoloso MS, et al. p27Kip1-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005;7:51-63 (Pubitemid 40126382)
16. Sugiyama Y, Tomoda K, Tanaka T, et al. Direct binding of the signal-transducing adaptor Grb2 facilitates down-regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem 2001;276:12084-90
17. Fujita N, Sato S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002;277:28706-13
18. Sekimoto T, Fukumoto M, Yoneda Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27. EMBO J 2004;23:1934-42 (Pubitemid 38902071)
19. Connor MK, Kotchetkov R, Cariou S, et al. CRM1/Ran-mediated nuclear export of p27Kip1 involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003;14:201-13 (Pubitemid 36106030)
20. Polyak K, Kato JY, Solomon MJ, et al. p27kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22
21. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996;137:3051-60 (Pubitemid 26192204)
22. Sa G, Guo Y, Stacey DW. The regulation of S phase initiation by p27Kip1 in NIH3T3 cells. Cell Cycle 2005;4:618-27 (Pubitemid 41359792)
23. Hitomi M, Yang K, Guo Y, et al. p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle 2006;5:2281-9 (Pubitemid 44546566)
24. Ji P, Zhu L. Using kinetic studies to uncover new Rb functions in inhibiting cell cycle progression. Cell Cycle 2005;4:373-5 (Pubitemid 41359718)
25. Larrea MD, Liang J, Da Silva T, et al. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol 2008;28:6462-72
26. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44
27. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 1996;85:721-32
28. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20
29. Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 2005;7:831-6 (Pubitemid 41079056)
30. Fero M, Randel E, Gurley K, et al. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-80 (Pubitemid 28523620)
31. Molatore S, Kiermaier E, Jung C, et al. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer 2010;9:116
32. Nguyen L, Besson A, Heng JI, et al. p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev 2006;20:1511-24 (Pubitemid 43830657)
33. Larrea MD, Hong F, Wander SA, et al. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci USA 2009;106:9268-73
34. McAllister SS, Becker-Hapak M, Pintucci G, et al. Novel p27kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 2003;23:216-28 (Pubitemid 36008515)
35. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998;4:1449-52 (Pubitemid 28553472)
36. Wu FY, Wang SE, Sanders ME, et al. Reduction of cytosolic p27Kip1 inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006;66:2162-72
37. Denicourt C, Saenz CC, Datnow B, et al. Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res 2007;67:9238-43 (Pubitemid 47535911)
38. Goukassian D, Diez-Juan A, Asahara T, et al. Overexpression of p27Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J 2001;11:1877-85 (Pubitemid 32848791)
39. Sun J, Marx SO, Chen HJ, et al. Role for p27Kip1 in vascular smooth muscle cell migration. Circulation 2001;103:2967-72 (Pubitemid 32578136)
40. Diez-Juan A, Andres V. Coordinate control of proliferation and migration by the p27Kip1cyclin-dependent kinase/Retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res 2003;92:402-10 (Pubitemid 36298200)
41. Supriatno, Harada K, Kawaguchi S, et al. Effect of p27Kip1 on the ability of invasion and metastasis of an oral cancer cell line. Oncol Rep 2003;10:527-32
42. Nguyen L, Besson A, Roberts JM, Guillemot F. Coupling cell cycle exit, neuronal differentiation and migration in cortical neurogenesis. Cell Cycle 2006;5:2314-18 (Pubitemid 44785839)
43. Schiappacassi M, Lovat F, Canzonieri V, et al. p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Canc Ther 2008;7:1164-75
44. Belletti B, Pellizzari I, Berton S, et al. p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol Cell Biol 2010;30:2229-40
45. Katayose Y, Kim M, Rakkar AN, et al. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57:5441-5 (Pubitemid 28006743)
46. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;12:1062-75 (Pubitemid 29008220)
47. Drexler HCA. The role of l. p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle 2003;2:438-41
48. Nickeleit I, Zender S, Sasse F, et al. Argyrin a reveals a critical role for the tumor suppressor protein p27kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008;14:23-35 (Pubitemid 351885496)
49. Hiromura K, Pippin JW, Fero ML, et al. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27Kip1. J Clin Invest 1999;103:597-604 (Pubitemid 29122412)
50. Dimanche-Boitrel M, Micheau O, Hammann A, et al. Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of colon carcinoma HT29 cells. Int J Cancer 1998;77:796-802 (Pubitemid 28341399)
51. Yang Q, Sakurai T, Yoshimura, et al. Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C. Anticancer Res 2000;20:4319-22 (Pubitemid 32141780)
52. Le TVT, Seo Y, Ryu CJ, et al. Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. Arch Pharm Res 2010;33:1127-32
53. Levkau B, Koyama H, Raines EW, et al. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998;4:553-63 (Pubitemid 128374691)
54. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27Kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218-24 (Pubitemid 46420865)
55. Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716-24 (Pubitemid 47311902)
56. Le Sage C, Nagel R, Egan DA, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26:3699-708 (Pubitemid 47236875)
57. Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007;14:791-8 (Pubitemid 350074067)
58. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61
59. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008;283:29897-903
60. Fu X, Wang Q, Chen J, et al. Clinical significance of miR-221 and its inverse correlation with p27Kip1 in hepatocellular carcinoma. Mol Biol Rep 2010: published online 10 February 2010, doi: 10.1007/s11033-010-9969-5
61. Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010;115:3949-59
62. Wurz K, Garcia RL, Goff BA, et al. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 2010;49:577-84
63. Kedde M, van Kouwenhove M, Zwart W, et al. A Pumilio-induced RNA structure switch in p27-3¢?UTR controls miR-221 and miR-222 accessibility. Nat Cell Biol 2010;12:1014-20
64. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors. Cell Cycle 2010;12:1-11
65. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;16:5334-44 (Pubitemid 27380141)
66. Montagnoli A, Fiore F, Eytan E, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999;13:1181-9 (Pubitemid 29233148)
67. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9 (Pubitemid 129500937)
68. Ganoth D, Bornstein G, Ko TK, et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001;3:321-4 (Pubitemid 32201330)
69. Zhou W, Yang Q, Low CB, et al. Pin1 catalyzes conformational changes of Thr-187 in p27Kip1 and mediates its stability through a polyubiquitination process. J Biol Chem 2009;284:23980-8
70. Denti S, Fernandez-Sanchez ME, Rogge L, Bianchi E. The COP9 signalosome regulates Skp2 levels and proliferation of human cells. J Biol Chem 2006;281:32188-96 (Pubitemid 46036773)
71. Li B, Jia N, Kapur R, Chun KT. Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis. Blood 2006;107:4291-9 (Pubitemid 43801353)
72. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27Kip1 at G1 phase. Nat Cell Biol 2004;6:1229-35 (Pubitemid 39625122)
73. Kotoshiba S, Kamura T, Hara T, et al. Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J Biol Chem 2005;280:17694-700 (Pubitemid 41389006)
74. Rodier G, Montagnoli A, Di Marcotullio L, et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001;20:6672-82 (Pubitemid 33134197)
75. Ishida N, Hara T, Kamura T, et al. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002;277:14355-8 (Pubitemid 34952496)
76. Delmas C, Aragou N, Poussard S, et al. MAP kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells requirement of p27Kip1 nuclear export. J Biol Chem 2003;278:12443-51 (Pubitemid 36800231)
77. Akashiba H, Matsuki N, Nishiyama N. Calpain activation is required for glutamate-induced p27 down-regulation in cultured cortical neurons. J Neurochem 2006;99:733-44 (Pubitemid 44583433)
78. Fuster JJ, Gonzalez JM, Edo MD, et al. Tumor suppressor p27Kip1 undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J 2010;24:2998-3009
79. Kotake Y, Nakayama K, Ishida N, Nakayama KI. Role of serine 10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 mutation. J Biol Chem 2005;280:1095-102
80. Besson A, Gurian-West M, Chen X, et al. Subcellular localization, and tumor suppression stability, Kip1 A pathway in quiescent cells that controls p27. Genes Dev 2006;20:47-64 (Pubitemid 43042667)
81. Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. Phosphorylation at serine 10, a major phosphorylation site of p27Kip1, increases its protein stability. J Biol Chem 2000;275:25146-54
82. Boehm M, Yoshimoto T, Crook MF, et al. A growth factor-dependent nuclear kinase phosphorylates p27Kip1 and regulates cell cycle progression. EMBO J 2002;21:3390-401 (Pubitemid 34760571)
83. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997;11:342-5 (Pubitemid 27120981)
84. Reed SI. Focus on p27. Keeping p27Kip1 in the cytoplasm. A second front in cancer's war on p27. Cell Cycle 2002;1:389-90
85. Fujita N, Sato S, Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 localization. J Biol Chem 2003;278:49254-60
86. Deng X, Mercer SE, Shah S, et al. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase. J Biol Chem 2004;279:22498-504 (Pubitemid 38679449)
87. Kawauchi T, Chihama K, Nabeshima YI, Hoshino M. Cdk5 phosphorylates and stabilizes p27Kip1 contributing to actin organization and cortical neuronal migration. Nat Cell Biol 2006;8:17-26 (Pubitemid 43064793)
88. Kajihara R, Fukushige S, Shioda N, et al. CaMKII phosphorylates serine 10 of p27 and confers apoptosis resistance to HeLa cells. Biochem Biophys Res Commun 2010;401:350-5
89. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153-60 (Pubitemid 35175971)
90. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-52 (Pubitemid 35175970)
91. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44 (Pubitemid 35175969)
92. Chu I, Sun J, Arnaout A, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007;128:281-94 (Pubitemid 46123510)
93. Grimmler M, Wang Y, Mund T, et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007;128:269-80 (Pubitemid 46123508)
94. Kardinal C, Dangers M, Kardinal A, et al. Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4. Blood 2006;107:1133-40 (Pubitemid 43156315)
95. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-67 (Pubitemid 351430863)
96. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1977;3:231-4
97. Lu CD, Morita S, Ishibashi T, et al. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999;85:1250-60 (Pubitemid 29125077)
98. Mineta H, Miura K, Suzuki I, et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 1999;85:1011-17 (Pubitemid 29115577)
99. Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002;94:973-9 (Pubitemid 34150851)
100. Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007;6:2005-9 (Pubitemid 47327888)
101. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54 (Pubitemid 46214304)
102. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008;112:1415-24 (Pubitemid 351441154)
103. Susaki E, Nakayama K, Nakayama KI. Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition. Mol Cell Biol 2007;27:4626-40 (Pubitemid 47016118)
104. He S, Lu M, Xue W, et al. Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro. Med Oncol 2010: published online 28 Janury 2010, doi: 10.1007/s12032-009-9408-4
105. Kim J, Jonasch E, Alexander A, et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009;15:81-90
106. Porter PL, Barlow WE, Yeh I-T, et al. p27Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006;98:1723-31 (Pubitemid 44942710)
107. Spataro VJ, Litman H, Viale G, et al. International breast cancer study group. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from international breast cancer study group trial, V. Cancer 2003;97:1591-600 (Pubitemid 36350701)
108. Sion-Vardy N, Freedman J, Lazarov I, et al. p27kip1 Expression in non-small cell lung cancer is not an independent prognostic factor. Anticancer Res 2010;30:3699-704
109. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45
110. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807 (Pubitemid 46606235)
111. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39 (Pubitemid 38637993)
112. Ono K, Sugio K, Uramoto H, et al. Discrimination of multiple primary lung cancers from intrapulmonary metastasis based on the expression of four cancer-related proteins. Cancer 2009;115:3489-500
113. Bertagnolli MM, Warren RS, Niedzwiecki D, et al. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res 2009;15:2116-22
114. Meyerhardt JA, Ogino S, Kirkner GJ, et al. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res 2009;15:5931-6
115. Watson NFS, Durrant LG, John H, et al. Cytoplasmic expression of p27Kip1 is associated with a favourable prognosis in colorectal cancer patients. World J Gastroenterol 2006;12:6299-304 (Pubitemid 44712410)
116. Manne U, Jhala NC, Jones J, et al. Prognostic significance of p27kip1 expression in colorectal adenocarcinomas is associated with tumor stage. Clin. Cancer Res 2004;10:1743-52 (Pubitemid 38435566)
117. Romics I, Banfi G, Szekely E, et al. Expression of p21waf1/cip1, p27kip1, p63 and androgen receptor in low and high gleason score prostate cancer. Pathol Oncol Res 2008;14:307-11
118. Li R, Wheeler TM, Dai H, et al. Biological correlates of p27 compartmental expression in prostate cancer. J Urol 2006;175:528-32 (Pubitemid 43067345)
119. Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia 2010;12:599-607
120. Chen Y, Guggisberg N, Jorda M, et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clinical Cancer Res 2009;15:3396-405
121. Andreu EJ, Lledo E, Enric Poch E, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005;65:3264-72 (Pubitemid 40524610)
122. Liu Y, Perdreau SA, Chatterjee P, et al. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. Cancer Res 2008;68:9015-23
123. Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202 (Pubitemid 33741894)
124. Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008;15:237-43
125. Chen JS, Faller DV. Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol 2005;202:87-99 (Pubitemid 39603365)
126. Borriello A, Della Pietra V, Criscuolo M, et al. p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene 2000;19:51-60 (Pubitemid 30066350)
127. Borriello A, Cucciolla V, Criscuolo M, et al. Retinoic acid induces p27Kip1 nuclear accumulation by modulating its phosphorylation. Cancer Res 2006;66:4240-8
128. Oliva A, Borriello A, Zeppetelli S, et al. Retinoic acid inhibits the growth of bone marrow mesenchymal stem cells and induces p27Kip1 and p16INK4A up-regulation. Mol Cell Biochem 2003;247:55-60 (Pubitemid 36798509)
129. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-57 (Pubitemid 351469448)
130. Baiz D, Pozzato G, Dapas B, et al. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 2009;91:373-82
131. Timmerbeul I, Garrett-Engele CM, Kossatz U, et al. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA 2006;103:14009-14 (Pubitemid 44452971)